New Therapy for Intractable Pulmonary Fibrosis using Humoral Factors released from Mesenchymal Stem Cells

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591149
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Tohoku University
• Principal Investigator: OHKOUCHI Shinya 東北大学, 環境・安全推進センター, 講師 (40375035)
• Co-Investigator(Kenkyū-buntansha): EBINA Masahito 東北薬科大学, 病院, 教授 (10280885)
• Co-Investigator(Renkei-kenkyūsha): KANEHIRA Masahiko 東北大学, 大学院医学研究科, 助教 (90374941)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 間葉系幹細胞 / 特発性肺線維症 / 間質性肺炎 / 小胞体ストレス / 過酸化ストレス

Outline of Final Research Achievements

Continuous ER-stress changes the secretary status of AECs and increase the synthesis, and secretion of pro-fibrotic humoral factors including TGF-beta 1 from AECs. TGF-beta 1 promotes the change from fibroblasts to myo-fibroblasts which is essential for the formation of fibrosis. Recent studies show that Mesenchymal stem cells (MSCs) ameliorate fibrosis in bleomycin inhalation mice (IPF model mice). MSCs can reduce ER-stress of cells in microenvironment under harmful conditions however that mechanism is still unknown. We has shown that protein hormone STC1 reduce endothelium reticulum stress (ER-stress) pulmonary fibrosis in Bleomycin-induced fibrosis mice. We published our work in Molecular Therapy, 2015, 23, 549.

Free Research Field

呼吸器内科